Gan & Lee Pharmaceuticals 2022 AR2
The report highlights Gan & Lee Pharmaceuticals' strategic progress and operational performance in 2022, particularly following the implementation of the national insulin volume-based procurement scheme. The company successfully expanded its domestic market presence, gaining access to nearly 16,000 new medical institutions and achieving a 29.77% year-on-year increase in domestic formulation sales. In research and development, the company advanced key pipelines, including the clinical trials of GZR18, GZR4, and GZR101. On the environmental front, the company invested 9.2374 million RMB in environmental protection and reduced carbon emissions by 508 tonnes, primarily through the implementation of photovoltaic power generation technology.
Company: Gan & Lee Pharmaceuticals
Sector: Health Care
Country: China
Year: 2022
Type: AR2
Pages: 375
Gan & Lee Pharmaceuticals
Annual Report
The report highlights Gan & Lee Pharmaceuticals' strategic progress and operational performance in 2022, particularly following the implementation of the national insulin volume-based procurement scheme. The company successfully expanded its domestic market presence, gaining access to nearly 16,000 new medical institutions and achieving a 29.77% year-on-year increase in domestic formulation sales. In research and development, the company advanced key pipelines, including the clinical trials of GZR18, GZR4, and GZR101. On the environmental front, the company invested 9.2374 million RMB in environmental protection and reduced carbon emissions by 508 tonnes, primarily through the implementation of photovoltaic power generation technology.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Type
Annual Report with Sustainability Disclosures
Language
English, Chinese
Pages
File Size
Standards & Assurance
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Employees